Sanofi (EURONEXT: SAN, NASDAQ: SNY) announced that its experimental drug lunsekimig achieved primary and key secondary endpoints in phase 2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE